A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays

Journal of Pharmacological and Toxicological Methods

Volumn 60, Issue 1, 2009, Pages 45-50

  Trepakova, Elena S ^a   Koerner, John ^b   Pettit, Syril D ^c   Valentin, Jean Pierre ^d  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Animal models; Cardiac repolarization; Cardiac safety; ILSI HESI; Pro Arrhythmia Models Project Committee; QT; QTc

Indexed keywords

POTASSIUM CHANNEL HERG;

ARTICLE; DATA ANALYSIS; DATA BASE; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HEART REPOLARIZATION; PREDICTION; QT PROLONGATION; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ACTION POTENTIALS; ANIMALS; ARRHYTHMIAS, CARDIAC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROCARDIOGRAPHY; GUIDELINES AS TOPIC; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; PROGRAM DEVELOPMENT; TORSADES DE POINTES;

ANIMALIA;

EID: 68749117480     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2009.05.002     Document Type: Article

References (45)

1. Ando K., Hombo T., Kanno A., Ikeda H., Imaizumi M., Shimizu N., et al. QT PRODACT: In vivo QT assay with a conscious monkey for assessment of the potential for drug-induced QT interval prolongation. Journal of Pharmacological Sciences 99 (2005) 487-500
2. Anon. ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (2005). http://www.emea.eu.int/pdfs/human/ich/042302en.pdf London, 25 May 2005. CPMP/ICH/423/02. http://www.emea.eu.int/pdfs/human/ich/042302en.pdf
3. Anon. ICH E14: The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs (2005). http://www.emea.eu.int/pdfs/human/ich/000204en.pdf London, 25 May 2005. CPMP/ICH/2/04. http://www.emea.eu.int/pdfs/human/ich/000204en.pdf
4. Anon. Cardiovascular Pro-Arrhythmia Models Project Committee. In ILSI HESI 2008 Annual Report, Washington, DC (2008) 27. http://www.hesiglobal.org/AboutUs/HESI+Annual+Report.htm http://www.hesiglobal.org/AboutUs/HESI+Annual+Report.htm
5. Bass A.S., Darpo B., Valentin J.P., Sager P., and Thomas K. Moving towards better predictors of drug-induced Torsades de Pointes. British Journal of Pharmacology 154 (2008) 1550-1553
6. Bass A.S., Darpo B., Breidenbach A., Bruse K., Feldman H.S., Garnes D., et al. Recommendations for areas of investigation from the workshop breakout sessions. Workshop: 'Moving towards better predictors of drug-induced torsade de pointe'. Crystal City, Virginia, U.S.A., November 2005, under the auspices of the Proarrhythmia Models Project Committee-International Life Sciences Institute-Health and Environmental Sciences Institute. British Journal of Pharmacology 154 (2008) 1491-1501
7. Cantilena Jr. L.R., Koerner J., Temple R., and Throckmorton D.C. FDA evaluation of cardiac repolarization data for 19 drugs and drug candidates. Clinical Pharmacology And Therapeutics 79 (2006) 2 (abstract)
8. Cavero I., and Crumb W. The use of electrocardiograms in clinical trials: A public discussion of the proposed ICH E14 regulatory guidance. April 11-12, 2005, Bethesda, MD, USA. Expert Opinion on Drug Safety 4 (2005) 795-799
9. Chinushi M., Restivo M., Caref E.B., and El-Sherif N. Electrophysiological basis of arrhythmogenicity of QT/T alternans in the long-QT syndrome: Tridimensional analysis of the kinetics of cardiac repolarization. Circulation Research 83 (1998) 614-628
10. Cordes J.S., Sun Z., Lloyd D.B., Bradley J.A., Opsahl A.C., Tengowski M.W., et al. Pentamidine reduces hERG expression to prolong the QT interval. British Journal of Pharmacology 145 (2005) 15-23
11. Duraković Z., Misigoj-Duraković M., and Corović N. QT and JT dispersion in the elderly with urban hypothermia. International Journal of Cardiology 80 (2001) 221-226
12. Eckhardt L.L., Rajamani S., and January C.T. Protein trafficking abnormalities: A new mechanism in drug-induced long QT syndrome. British Journal of Pharmacology 145 (2005) 3-4
13. Ficker E., Kuryshev Y.A., Dennis A.T., Obejero-Paz C., Wang L., Hawryluk P., et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Molecular Pharmacology 66 (2004) 33-44
14. Fossa A.A., Wisialowski T., Magnano A., Wolfgang E., Winslow R., Gorczyca W., et al. Dynamic beat-to-beat modeling of the QT-RR interval relationship: Analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. Journal of Pharmacology and Experimental Therapeutics 312 (2005) 1-11
15. Hanson L.A., Bass A.S., Gintant G., Mittlestadt S., Rampe D., and Thomas K. ILSI-HESI cardiovascular safety subcommittee initiative: Evaluation of three non-clinical models of QT prolongation. Journal of Pharmacological & Toxicological Methods 54 (2006) 116-129
16. Heller S.R. Abnormalities of the electrocardiogram during hypoglycaemia: The cause of the dead in bed syndrome?. International Journal of Clinical Practice. Supplement 129 (2002) 27-32
17. Huang C.H., Tsai M.S., Hsu C.Y., and Chen W.J. Images in cardiovascular medicine. Therapeutic hypothermia-related torsade de pointes. Circulation 114 (2006) e521-e522
18. Koerner J. FDA perspectives on furthering scientific efforts to define CV safety. QT and Arrhythmia Issues in Drug Development, DIA, Hyatt Regency Bethesda, Bethesda, MD, USA, April 7-8 (2008)
19. Kuryshev Y.A., Ficker E., Wang L., Hawryluk P., Dennis A.T., Wible B.A., et al. Pentamidine-induced long QT syndrome and block of hERG trafficking. Journal of Pharmacology and Experimental Therapeutics 312 (2005) 316-323
20. Kuryshev Y.A., Wang L., Wible B.A., Wan X., and Ficker E. Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents. Molecular Pharmacology 69 (2006) 1216-1225
21. Lacerda A.E., Kuryshev Y.A., Chen Y., Renganathan M., Eng H., Danthi S.J., et al. Alfuzosin delays cardiac repolarization by a novel mechanism. Journal of Pharmacology and Experimental Therapeutics 324 (2008) 427-433
22. Lathrop D.A., Contney S.J., Bosnjak Z.J., and Stowe D.F. Reversal of hypothermia-induced action potential lengthening by the KATP channel agonist bimakalim in isolated guinea pig ventricular muscle. General Pharmacology 31 (1998) 125-131
23. Lawrence C.L., Pollard C.E., Hammond T.G., and Valentin J.P. In vitro models of proarrhythmia. British Journal of Pharmacology 154 (2008) 1516-1522
24. Marfella R., Rossi F., and Giugliano D. Hyperglycemia and QT interval: Time for re-evaluation. Diabetes, Nutrition & Metabolism 14 (2001) 63-65
25. Martin R.L., McDermott J.S., Salmen H.J., Palmatier J., Cox B.F., and Gintant G.A. The utility of hERG and repolarization assays in evaluating delayed cardiac repolarization: Influence of multi-channel block. Journal of Cardiovascular Pharmacology 43 (2004) 369-379
26. Mitcheson J.S., Chen J., Lin M., Culberson C., and Sanguinetti M.C. A structural basis for drug-induced long QT syndrome. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 12329-12333
27. Miyazaki H., Watanabe H., Kitayama T., Nishida M., Nishi Y., Sekiya K., et al. QT PRODACT: Sensitivity and specificity of the canine telemetry assay for detecting drug-induced QT interval prolongation. Journal of Pharmacological Sciences 99 (2005) 523-529
28. Newbold P., Sanders N., and Reele S.B. Lack of correlation between exercise and sibenadet-induced changes in heart rate corrected measurement of the QT interval. British Journal of Clinical Pharmacology 63 (2007) 279-287
29. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regulatory Toxicology and Pharmacology 32 (2000) 56-67
30. Omata T., Kasai C., Hashimoto M., Hombo T., and Yamamoto K. QT PRODACT: Comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. Journal of Pharmacological Sciences 99 (2005) 531-541
31. Oros A., Beekman J.D., and Vos M.A. The canine model with chronic, complete atrio-ventricular block. Pharmacology & Therapeutics 119 (2008) 168-178
32. Pollard C.E., Valentin J.P., and Hammond T.G. Strategies to reduce the risk of drug-induced QT interval prolongation: A pharmaceutical company perspective. British Journal of Pharmacology 154 (2008) 1538-1543
33. Pugsley M.K., Authier S., and Curtis M.J. Principles of safety pharmacology. British Journal of Pharmacology 154 (2008) 1382-1399
34. Robinson R.T., Haris N.D., Ireland R.H., Lee S., Newman C., and Heller S.R. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycaemia. Diabetes 52 (2003) 1469-1474
35. Roden D.M. Cellular basis of drug induced torsades de pointes. British Journal of Pharmacology 154 (2008) 1502-1507
36. Ks: Potential for antiarrhythmic therapy. Current Medicinal Chemistry 11 (2004) 29-44
37. Sasaki H., Shimizu N., Suganami H., and Yamamoto K. QT PRODACT: Inter-facility variability in electrocardiographic and hemodynamic parameters in conscious dogs and monkeys. Journal of Pharmacological Sciences 99 (2005) 513-522
38. Tamargo J. Drug-induced torsade de pointes: From molecular biology to bedside. Japanese Journal of Pharmacology 83 (2000) 1-19
39. Titier K., Canal M., Deridet E., Abouelfath A., Gromb S., Molimard M., et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: Comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicology and Applied Pharmacology 199 (2004) 52-60
40. Valentin J.P., Newbold P., and Hammond T.G. Predictive value of non-clinical models to assess QT liability in man: Sibenadet (Viozan™, ARC-68397AA), a case study. Journal of Pharmacological and Toxicological Methods 54 (2006) 253
41. + channels: Friend and foe. Trends in Pharmacological Sciences 22 (2001) 240-246
42. Vos M.A. Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability. British Journal of Pharmacology 154 (2008) 1523-1527
43. Wallis, R., (submitted for publication). Integrated risk assessment and predictive value to humans of non-clinical repolarization assays. British Journal of Pharmacology.
44. Wible B.A., Hawryluk P., Ficker E., Kuryshev Y.A., Kirsch G., and Brown A.M. HERG-Lite: A novel comprehensive high-throughput screen for drug-induced hERG risk. Journal of Pharmacological and Toxicological Methods 52 (2005) 136-145
45. Witchel H.J., Dempsey C.E., Sessions R.B., Perry M., Milnes J.T., Hancox J.C., et al. The low-potency, voltage-dependent HERG blocker propafenone-Molecular determinants and drug trapping. Molecular Pharmacology 66 (2004) 1201-1212